Michal Shavit, Scientist at Eloxx Pharmaceutical

Michal Shavit

Scientist at Eloxx Pharmaceutical

links
https://il.linkedin.com/in/michal-shavit-0896768

Experience

Scientist

Eloxx Pharmaceutical

September 2016 – Present (2 months)Ness Ziona

Research Scientist

Recipharm

October 2015 – September 2016 (1 year)Ness Ziona, Israel

Postdoctoral Researcher

Technion - Israel Institute of Technology

March 2015 – September 2015 (7 months)Haifa

Teaching Assistant

Technion - Israel Institute of Technology

October 2010 – September 2015 (5 years)Haifa Area, Israel

Research Assistant

Columbia University

July 2008 – July 2009 (1 year 1 month)

Education

Technion - Israel Institute of Technology

Doctor of Philosophy (PhD), Chemistry

2010 – 2015

The Hebrew University

Master of Science (MSc), Chmistry

2004 – 2007

The Hebrew University of Jerusalem

Bachelor’s Degree, Chmistry

2001 – 2004

ort Maalot

Publications

Active cytotoxic reagents based on non-metallocene non-diketonato well-defined C2-symmetrical titanium complexes of tetradentate bis(phenolato) ligands(Link)

J. Am. Chem. Soc.

September 18, 2007

Structural characterization of dinuclear Ti(IV) complexes of rigid tetradentate dianionic diamine bis(phenolato) ligands; effect of steric bulk on coordination features(Link)

Journal of Organometallic Chemistry

October 4, 2008

Antitumor Reactivity of Non-Metallocene Titanium Complexes of Oxygen-Based Ligands: is Ligand Lability Essential?(Link)

J. Biol. Inorg. Chem.

July 2007

Preparation and X-Ray Structures of Ti(IV) Complexes of Bis(carboxylato) Ligands; Formation of Mono-, Di-, Tetra- and Hexanuclear Complexes With or Without OR and μ-O Ligands

Eur. J. Inorg. Chem.

2008

• --

Synthesis, Characterization, Cytotoxicity, and Hydrolytic Behavior of C2 and C1-Symmetrical Ti(IV) Complexes of Tetradentate Diamine Bis(Phenolato) Ligands: A New Class of Antitumor Agents

Chem. Eur. J

2009

• --

TiIV Complexes of Branched Diamine Bis(phenolato) Ligands: Hydrolysis and Cytotoxicity

Eur. J. Inorg. Chem.

2011

• --

Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations

Journal of Medicinal Chemistry

2012

A hybrid drug limits resistance by evading the action of the multiple antibiotic resistance pathway.(Link)

Molecular Biology and Evolution

November 3, 2015

Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations

ACS Medicinal Chemistry Letters

February 8, 2016


//////////////